EG 427 announces issuance of the first 2 patents for its HSV-based gene therapy treatment.
April 11, 2023- Issued European and Japanese patents cover herpes simplex virus (HSV) vectors selectively inhibiting subtype of sensory neurons
- Related initial therapeutic indications encompass multiple bladder conditions with a first focus on neurogenic detrusor overactivity
Read full press release in English or in French